Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific stem cell memory cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Atara Biotherapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational adoptive cell therapy developed by researchers at University Hospital Basel, Switzerland. It consists of donor-derived Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) enriched for a stem cell memory (Tscm) phenotype. These cells are characterized by high proportions of CD4+ T cells and broad coverage of EBV antigens. The therapy is designed to provide long-term immune surveillance and effector function against EBV-infected cells. It is currently being evaluated in Phase I/II clinical trials for treatment-refractory EBV-driven diseases, including post-transplant lymphoproliferative disease (PTLD), EBV-associated lymphomas, hemophagocytic lymphohistiocytosis (HLH), and chronic active EBV infection (CAEBV).
- Other names
- Donor-derived ex-vivo expanded EBV Tscm CTLEBV-specific T memory stem cell therapy
02
Targets
EBNA1 (Epstein-Barr virus latency proteins)
Beyond the preview
Go deeper on EBV-specific stem cell memory cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific stem cell memory cytotoxic T lymphocytes.